Phenanthroline

Phenanthroline

SCHEMBL4577706

CNC1(NC)CCCCC1.[Pt].c1cnc2c(c1)ccc1cccnc12

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.52
CCR1 P32246 4/20 0.52
CCR8 P51685 4/20 0.52
TDP1 Q9NUW8 4/20 0.52
KDM4E B2RXH2 4/20 0.52
MAPT P10636 4/20 0.52
CCR5 P51681 3/20 0.52
HTT P42858 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MMP2 P08253 2/20 0.52
TSHR P16473 2/20 0.52
ALOX15 P16050 2/20 0.52
GMNN O75496 1/20 0.52
TP53 P04637 1/20 0.52
HSP90AA1 P07900 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
MMP9 P14780 1/20 0.52
NFKB1 P19838 1/20 0.52
MMP8 P22894 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthroline SCHEMBL4576856 0.78 LMNA (0.57) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL5726130 0.76 CCR1 (0.50) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL4617743 0.74 CCR1 (0.94) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL29354015 0.72 CCR1 (1.00) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL29367277 0.72 CCR1 (1.00) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL8845760 0.72 CCR1 (1.00) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL8312 0.72 CCR1 (1.00) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL9343811 0.70 KDM4E (0.84) LMNACCR1CCR8TDP1KDM4E
Phenanthroline SCHEMBL25423982 0.70 LMNA (0.55) LMNACCR1CCR8TDP1KDM4E
SCHEMBL6763506 0.70 LMNA (0.50) LMNACCR1CCR8TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410960-B2 Metal complexes and therapeutic uses thereof THE UNIVERSITY OF WESTERN SYDNEY (AU) 2008-08-12 US claimed
EP-1377552-B1 METAL COMPLEXES AND THERAPEUTIC USES THEREOF UNIV SYDNEY (AU) 2006-05-17 EP claimed
US-20040152686-A1 Metal complexes and therapeutic uses thereof THE UNIVERSITY OF WESTERN SYDNEY (AU) 2004-08-05 US claimed
US-7410960-B2 Metal complexes and therapeutic uses thereof THE UNIVERSITY OF WESTERN SYDNEY (AU) 2008-08-12 US disclosed
EP-1377552-B1 METAL COMPLEXES AND THERAPEUTIC USES THEREOF UNIV SYDNEY (AU) 2006-05-17 EP disclosed
US-20040152686-A1 Metal complexes and therapeutic uses thereof THE UNIVERSITY OF WESTERN SYDNEY (AU) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152686-A1 Metal complexes and therapeutic uses thereof SOD1, PDCD1LG2, SLC30A5 LMNA 1585/4885CCR1 173/4885CCR8 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.